Drug intelligence / Profile preview

HAPC1573

Development stage: Preclinical
Lead developer: Bayer
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

HAPC1573 is a murine monoclonal antibody (IgG1/κ) that selectively binds to human activated protein C (APC) and inhibits its anticoagulant activity without affecting its cytoprotective or anti-inflammatory functions. Originally developed at the Oklahoma Medical Research Foundation (OMRF), HAPC1573 serves as the parent antibody of SR604, a humanized monoclonal antibody being developed by Equilibra Bioscience and Shanghai RAAS for the treatment of hemophilia A, hemophilia B, and other bleeding disorders. By blocking the anticoagulant function of APC, HAPC1573 helps to rebalance the coagulation cascade, promoting thrombin generation and clot stability in factor-deficient environments.

Targets

PROC (Vitamin K-dependent protein C)

Beyond the preview

Go deeper on HAPC1573.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HAPC1573.

Explore the full profile